Enlivex Webinar to Present 3-Month Topline Data on Knee Osteoarthritis
Session to Highlight Findings from Study Evaluating Allocetra™
Enlivex Therapeutics Ltd. (NASDAQ: ENLV), renowned for its innovative macrophage reprogramming immunotherapy approaches, is preparing to host an engaging webinar centered on the impressive findings from its latest clinical study on knee osteoarthritis. Mark your calendars for this insightful session, where significant topline data from the Phase IIa trial will be spotlighted.
This upcoming webinar is scheduled for August 18, 2025, at 8:00 AM Eastern Time. Participants can expect comprehensive discussions regarding the data derived from the double-blind, randomized, placebo-controlled research. This clinical trial is a pivotal step in exploring how Allocetra™ can transform treatment protocols for patients afflicted by moderate to severe knee osteoarthritis.
Details About the Phase IIa Clinical Trial
The Phase I/IIa ENX-CL-05-001 trial investigates Allocetra™ across various parameters including patient safety, tolerability, and dosing. The primary objectives also encompass assessing the effectiveness of the treatment with a focus on alleviating joint pain and improving functionality over specified time frames of 3, 6, and 12 months after injection.
As the clinical trial progresses, a significant interim analysis has been performed by an independent body, which aims to potentially expand patient enrollment. Currently, the study has seen 134 participants complete the 3-month follow-up, representing a crucial timepoint for measuring key endpoints.
The Impact of Osteoarthritis
Osteoarthritis stands as the most prevalent form of arthritis globally, impacting over 300 million individuals, including more than 32.5 million in the United States alone. This degenerative joint disease can lead to debilitating conditions, affecting both men and women. Alarmingly, up to 47% of women and 40% of men can expect to face symptomatic knee osteoarthritis within their lifetimes, highlighting the urgent need for effective treatment solutions.
Phase I Trial Insights
Prior to launching the Phase IIa study, Enlivex successfully completed a Phase I open-label dose-escalation trial that focused on assessing the safety parameters and determining optimal dosing strategies. The feedback gathered from this study has been instrumental in shaping the ongoing research initiatives.
About Enlivex Therapeutics
Enlivex Therapeutics is firmly positioned at the forefront of immunotherapy innovation, developing Allocetra™, a versatile cell therapy designed to recalibrate the immune response by reprogramming macrophages back to their homeostatic state. Such a shift is critical for mitigating life-threatening and debilitating ailments.
For more insights about Enlivex Therapeutics and their groundbreaking work, please visit their official website.
Frequently Asked Questions
What is the focus of Enlivex's upcoming webinar?
The webinar will concentrate on presenting the 3-month topline results from their Phase IIa trial, highlighting the effectiveness of Allocetra™.
How many patients have completed the 3-month follow-up in the trial?
A total of 134 patients have successfully completed the 3-month follow-up period in the ongoing Phase IIa trial.
What are the main objectives of the ENX-CL-05-001 trial?
The trial primarily assesses safety, tolerability, efficacy, and impacts on joint pain and functionality in patients with knee osteoarthritis.
Why is knee osteoarthritis a significant health issue?
Knee osteoarthritis affects a substantial portion of the population, leading to severe discomfort and impairing daily activities, making effective treatments critically important.
How does Allocetra™ work in patients?
Allocetra™ works by reprogramming macrophages to restore them to their normal state, which is essential for balancing the immune system and addressing serious health conditions.
